(Q38118853)

29 August 2017

title

Fenofibrate-associated nephrotoxicity: a review of current evidence (English)

1 reference

29 August 2017

3

Laurajo Ryan

1 reference

29 August 2017

2

Christopher R Frei

1 reference

29 August 2017

1

Rebecca L Attridge

1 reference

29 August 2017

Jim Koeller

4

1 reference

29 August 2017

William D Linn

series ordinal

5

1 reference

29 August 2017

publication date

1 July 2013

1 reference

American Journal of Health-System Pharmacy

29 August 2017

published in

1 reference

29 August 2017

volume

70

1 reference

29 August 2017

issue

14

1 reference

29 August 2017

page(s)

1219-1225

1 reference

In the clinic. Dyslipidemia

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Fibrates: what have we learned in the past 40 years?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Fibrate therapy: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Hypertriglyceridemia and cardiovascular risk reduction.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Hypertriglyceridemia: its etiology, effects and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Effects of combination lipid therapy in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Safety considerations with fibrate therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Fenofibrate-Induced elevation in serum creatinine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Elevated serum creatinine levels associated with fenofibrate therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Fenofibrate increases creatininemia by increasing metabolic production of creatinine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Acute kidney injury: epidemiology and diagnostic criteria.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120131

31 March 2020

Identifiers

DOI

10.2146/AJHP120131

1 reference

29 August 2017

1 reference